Noile-Immune Biotech Inc.
4893.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.42 | -0.04 | 1.48 | -1.49 |
| FCF Yield | -12.06% | -9.93% | -0.38% | -2.64% |
| EV / EBITDA | -2.52 | -4.17 | -220.83 | -32.91 |
| Quality | ||||
| ROIC | -22.60% | -13.62% | -2.47% | -18.32% |
| Gross Margin | 97.43% | 99.29% | 98.87% | 77.27% |
| Cash Conversion Ratio | 0.92 | 0.77 | 0.28 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | -77.03% | 46.51% | 85.98% | 4,652,786.79% |
| Free Cash Flow Growth | -1.69% | -714.62% | 86.21% | -158.49% |
| Safety | ||||
| Net Debt / EBITDA | 4.37 | 7.17 | 42.51 | 5.39 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.11 | 1.80 | 5.36 |
| Cash Conversion Cycle | 2,088.88 | 430.70 | -11,031.44 | -227.70 |